Several preclinical studies and case studies reported safety, activity and efficacy of the JAK inhibitor, ruxolitinib, in BCR::ABL1-like ALL harboring JAK-STAT-activating aberrations and ABL-class inhibitors in cases with rearrangements of ABL-class genes [6, 10, 14, 23–28]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.